Regulus Therapeutics Inc. (RGLS) Dividend History

Company News

• Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

  Novartis announces data from a subgroup analysis of the NATALEE trial, showing that Kisqali plus endocrine therapy reduced the risk of recurrence in pre-menopausal and younger patients with early breast cancer.

  GlobeNewswire Inc.
• Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

  Novartis has agreed to acquire Regulus Therapeutics, a clinical-stage biopharmaceutical company developing microRNA therapeutics for kidney diseases, for an initial payment of $800 million. The deal could reach $1.7 billion if Regulus' lead product candidate, farabursen, gains regulatory approval.

  Benzinga
• Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

  Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.

  Zacks Investment Research

  Featured Companies: ACAD AMLX MRNA REGN
• How Communities Impact Penny Stocks, 3 Ways

  Here's how communities impact penny stocks in 2024 The post How Communities Impact Penny Stocks, 3 Ways appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: CLRO